4/A: Compass Therapeutics GC Jonathan Anderman Buys Shares

General Counsel Jonathan Anderman acquired 25,000 shares of Compass Therapeutics common stock in an open market purchase.

Summary

• Jonathan Anderman, General Counsel of Compass Therapeutics, Inc., purchased 25,000 shares of common stock.
• The transaction occurred on April 29, 2026, at a price of $1.89 per share.
• Following this transaction, the reporting person holds a total of 196,000 shares.
• This filing serves as an amendment to correct the transaction code from 'A' (grant) to 'P' (open market purchase).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal because an executive is using their own capital to increase their stake in the company, despite the minor administrative correction required.

Positives

• Insider confidence is demonstrated by the General Counsel's decision to purchase shares with personal capital.
• The purchase price of $1.89 per share provides a clear reference point for market valuation.

Negatives

• The original filing contained an administrative error regarding the transaction code, necessitating this amendment.

Risks

• The company's equity compensation structure includes 150,000 unvested restricted stock units (RSUs) subject to service-based vesting, which may impact future dilution.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing instead on historical insider transaction reporting.

Management Comments

• The amendment clarifies that the transaction was an open market purchase rather than a grant.

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed by market participants as a positive signal regarding management's belief in the company's clinical pipeline and long-term valuation.

Comparison to Industry Standards

• Insider purchases by C-suite executives are generally considered a standard bullish indicator in the small-cap biotech industry.
• The transaction size is consistent with typical executive equity accumulation patterns for companies of this market capitalization.

Stakeholder Impact

• Shareholders may interpret the insider purchase as a sign of internal confidence in the company's future prospects.

Next Steps

• Vesting of the first installment of 150,000 RSUs on January 2, 2027.

Key Dates

Recommendation

While insider buying is a positive signal, a single purchase by a General Counsel is generally not sufficient to trigger a 'buy' rating without broader fundamental catalysts or institutional accumulation trends.

Keywords

Compass Therapeutics, CMPX, Insider Trading, Form 4, Biotech, Equity Purchase